S213: EFFICACY AND SAFETY OF HUMANIZED VERSUS MURINIZED CD19 AND CD22 CAR-T CELL COCKTAIL THERAPY FOR REFRACTORY/RELAPSED B-CELL LYMPHOMA
Main Authors: | L. Huang, J. Li, J. Yang, X. Zhang, M. Zhang, J. He, G. Zhang, Y. Su, W. Li, H. Wang, P. Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843744.47241.17 |
Similar Items
-
Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
by: Lefu Huang, et al.
Published: (2022-12-01) -
P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
by: Wenjing Luo, et al.
Published: (2023-08-01) -
Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
by: Changju Qu, et al.
Published: (2022-08-01) -
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
by: Peiling Zhang, et al.
Published: (2022-10-01) -
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
by: Barbara Savoldo, et al.
Published: (2023-08-01)